Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Regeneron unveils positive data from COVID-19 study for hospitalized patients on low-flow oxygen 

By Brian Buntz | December 29, 2020

RegeneronAfter receiving emergency use authorization (EUA) for the combination of casirivimab and imdevimab to treat COVID-19, Regeneron Pharmaceuticals (NSDQ:REGN) has announced promising early results in an ongoing trial involving hospitalized patients needing low-flow oxygen. 

Focusing on patients who had not yet developed an immune response to SARS-CoV-2, the trial found that patients who received the antibody cocktail had approximately half the risk of death or requiring mechanical ventilation one week after treatment.

The institutional review board has permitted the Phase 1/2/3 study to continue after it passed a futility analysis.  

The study also revealed a difference in performance between seronegative patients (who lacked antibodies to SARS-CoV-2) and seropositive patients (who had developed antibodies to the novel coronavirus).  

While the benefits for seronegative patients were clear, seropositive patients receiving the antibody cocktail had more modest improvements. 

“These preliminary results in hospitalized patients, as well as data from the previously announced outpatient trial, indicate that antibodies produced by a patient’s own immune response are important to control COVID-19 infection,” said Dr. George D. Yancopoulos, president and chief scientific officer at Regeneron in a statement.

Yancopoulos expressed optimism that the company’s antibody cocktail could “compensate for an inadequate endogenous antibody response by reducing viral levels and the risk of adverse clinical outcomes.” 

Yancopoulos stressed that the clinical efficacy data thus far is based on a small data set. 

The ongoing RECOVERY trial in the U.K. has enrolled more than 2,000 hospitalized patients in an arm testing the antibody cocktail against the standard of care. 

Federal officials are apparently disappointed that the monocolonal antibodies from Regeneron and Eli Lilly  (NYSE:LLY) have thus far found limited use after winning EUA, according to a report from NPR.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development

 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50